[CITATION][C] New oral thiazolidinedione antidiabetic agents act as insulin sensitizers
CA Hofmann, JR Colca - Diabetes care, 1992 - Am Diabetes Assoc
CA Hofmann, JR Colca
Diabetes care, 1992•Am Diabetes AssocOf the 12 million people in the US afflicted with NIDDM (1), nearly 40% are currently being
treated with oral hypoglycemic agents (2); it is clearly imperative to seek optimal treatment
for these patients. Development of treatment agents has followed principally from empirical
observations of potent hypoglycemic actions. Intense recent research studies have
produced an enhanced understanding of cellular derangements underlying the NIDDM
condition. The identification of specific cellular deficits in NIDDM presents opportunities for …
treated with oral hypoglycemic agents (2); it is clearly imperative to seek optimal treatment
for these patients. Development of treatment agents has followed principally from empirical
observations of potent hypoglycemic actions. Intense recent research studies have
produced an enhanced understanding of cellular derangements underlying the NIDDM
condition. The identification of specific cellular deficits in NIDDM presents opportunities for …
Of the 12 million people in the US afflicted with NIDDM (1), nearly
40% are currently being treated with oral hypoglycemic agents (2); it is clearly imperative to seek optimal treatment for these patients. Development of treatment agents has followed principally from empirical observations of potent hypoglycemic actions. Intense recent research studies have produced an enhanced understanding of cellular derangements underlying the NIDDM condition. The identification of specific cellular deficits in NIDDM presents opportunities for development of targeted treatments.
NIDDM is now known to involve several anomalies. These include I) aberrant pancreatic insulin secretion and 2) insulin resistance in peripheral tissues, with reduced glucose uptake particularly in muscle, and hepatic glucose overproduction (3-8). Although the order of appearance of these derangements during development of diabetes remains unknown, the overt diabetic condition is characterized by the coexistence of defective insulin secretion with insulin resistance. When fasting hyperglycemia becomes severe, ie,> 12 mM, the abil-
Am Diabetes Assoc